Stockscreener 앱 받기
1.16
4.92%
-0.06
시간 외 거래:
1.19
0.03
+2.59%
전일 마감가:
$1.22
열려 있는:
$1.23
하루 거래량:
263.70K
Relative Volume:
0.93
시가총액:
$36.19M
수익:
$1.05M
순이익/손실:
$-48.82M
주가수익비율:
-0.6339
EPS:
-1.83
순현금흐름:
$-47.49M
1주 성능:
-10.08%
1개월 성능:
-7.94%
6개월 성능:
-83.24%
1년 성능:
-78.44%
1일 변동 폭
$1.16
$1.24
1주일 범위
$1.16
$1.33
52주 변동 폭
$1.10
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
명칭
Actinium Pharmaceuticals Inc
전화
646-767-3870
주소
275 Madison Avenue, 7th Floor, New York, NY
ATNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.16 | 36.19M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-02-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 개시 | B. Riley Securities | Buy |
| 2020-11-05 | 개시 | Alliance Global Partners | Buy |
| 2017-12-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-14 | 개시 | Maxim Group | Buy |
| 2016-08-25 | 개시 | ROTH Capital | Buy |
| 2016-02-29 | 개시 | H.C. Wainwright | Buy |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2014-10-01 | 개시 | MLV & Co | Buy |
| 2014-07-22 | 개시 | Canaccord Genuity | Buy |
모두보기
Actinium Pharmaceuticals Inc 주식(ATNM)의 최신 뉴스
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Barclays PLC Buys 32,784 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis - MarketBeat
Jane Street Group LLC Sells 24,392 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Geode Capital Management LLC Has $1.29 Million Stock Holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Announces Executive Appointments - Marketscreener.com
Actinium Pharmaceuticals, Inc. Appoints Richard Stone to Scientific Advisory Board - Marketscreener.com
Actinium Pharmaceuticals, Inc. Announces Executive Appointments - Marketscreener.com
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
What Awaits Actinium In Q4? - RTTNews
Actinium Pharmaceuticals, Inc. Appoints Robert N. Daly as Vice President, Head of Clinical Operations - Marketscreener.com
Wellington Management Group LLP Acquires Shares of 59,608 Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Charles Schwab Investment Management Inc. Has $136,000 Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
ATNM stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
My Top 2 Stock Picks For A 2025 Rebound - Seeking Alpha
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Actinium stock plunges to 52-week low at $1.33 amid market challenges - Investing.com
Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes - TipRanks
Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress - TipRanks
Actinium Pharma keeps stock target with Buy rating on Q3 earnings - Investing.com UK
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - PR Newswire
Actinium Pharmaceuticals Reports $78.6M Cash Position, FDA Trial Clearances in Q3 - StockTitan
HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium: Q3 Earnings Snapshot - mySA
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts - Defense World
Actinium Pharmaceuticals Inc (ATNM) Quarterly 10-Q Report - Quartz
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire
Actinium Pharmaceuticals Appoints June Almenoff to its Board of Directors - citybiz
Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN
The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times
Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR
Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World
Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World
Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN
Wall Street SWOT: Actinium stock rides wave of targeted therapy innovation - Investing.com
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
Actinium Pharmaceuticals Inc (ATNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):